119th Congress · introduced in the House · Jun 24, 2026
Access to Innovative Treatments Act of 2026
Official title from Congress.gov
Latest action (Jun 24, 2026): Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Jun 24, 2026)
Access to Innovative Treatments Act of 2026
This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.
Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.
The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
5 citations.
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
…PIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
USAGAINSTALZHEIMERS ACTION · lobbying firm or registrant: USAGAINSTALZHEIMERS ACTION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
…ds for disability insurance benefits and Medicare coverage for individuals with young-onset Alzheimer's, and for other purposes; H.R. 6130, S. 3267 - ASAP Act; H.R. 9418 - Access to Innovative Treatments Act of 2026; H.R. 9495 - Department of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human S…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
USAGAINSTALZHEIMERS ACTION · lobbying firm or registrant: USAGAINSTALZHEIMERS ACTION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$150,000
Spent on own lobbying
…of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R. 9418 - Access to Innovative Treatments Act of 2026; H.R. 6799 - To amend title II of the Social Security Act to eliminate the waiting periods for disability insuran…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
USAGAINSTALZHEIMERS ACTION · lobbying firm or registrant: USAGAINSTALZHEIMERS ACTION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$130,000
Spent on own lobbying
…ds for disability insurance benefits and Medicare coverage for individuals with young-onset Alzheimer's, and for other purposes; H.R. 6130, S. 3267 - ASAP Act; H.R. 9418 - Access to Innovative Treatments Act of 2026; H.R. 9495 - Department of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human S…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
USAGAINSTALZHEIMERS ACTION · lobbying firm or registrant: USAGAINSTALZHEIMERS ACTION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$130,000
Spent on own lobbying
…of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R. 9418 - Access to Innovative Treatments Act of 2026; H.R. 6799 - To amend title II of the Social Security Act to eliminate the waiting periods for disability insuran…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing